Complement activation products in acute heart failure: Potential role in pathophysiology, responses to treatment and impacts on long-term survival
Standard
Complement activation products in acute heart failure: Potential role in pathophysiology, responses to treatment and impacts on long-term survival. / Trendelenburg, Marten; Stallone, Fabio; Pershyna, Kateryna; Eisenhut, Timo; Twerenbold, Raphael; Wildi, Karin; Dubler, Denise; Schirmbeck, Lucia; Puelacher, Christian; Rubini Gimenez, Maria; Sabti, Zaid; Osswald, Luca; Breidthardt, Tobias; Müller, Christian.
In: EUR HEART J-ACUTE CA, Vol. 7, No. 4, 06.2018, p. 348-357.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Complement activation products in acute heart failure: Potential role in pathophysiology, responses to treatment and impacts on long-term survival
AU - Trendelenburg, Marten
AU - Stallone, Fabio
AU - Pershyna, Kateryna
AU - Eisenhut, Timo
AU - Twerenbold, Raphael
AU - Wildi, Karin
AU - Dubler, Denise
AU - Schirmbeck, Lucia
AU - Puelacher, Christian
AU - Rubini Gimenez, Maria
AU - Sabti, Zaid
AU - Osswald, Luca
AU - Breidthardt, Tobias
AU - Müller, Christian
PY - 2018/6
Y1 - 2018/6
N2 - BACKGROUND: Previous studies have indicated a correlation between heart failure, inflammation and poorer outcome. However, the pathogenesis and role of inflammation in acute heart failure (AHF) is incompletely studied and understood. The aim of our study was to explore the potential role of innate immunity - quantified by complement activation products (CAPs) - in pathophysiology, responses to treatment and impacts on long-term survival in AHF.METHODS: In a prospective study enrolling 179 unselected patients with AHF, plasma concentrations of C4d, C3a and sC5b-9 were measured in a blinded fashion on the first day of hospitalisation and prior to discharge. The final diagnosis, including the AHF phenotype, was adjudicated by two independent cardiologists. Long-term follow-up was obtained. Findings in AHF were compared to that obtained in 75 healthy blood donors (control group).RESULTS: Overall, concentrations of all three CAPs were significantly higher in patients with AHF than in healthy controls (all p < 0.001). In an age-adjusted subgroup analysis, significant differences could be confirmed for concentrations of C4d and sC5b-9, and these parameters further increased after 6 days of in-hospital treatment ( p < 0.001). In contrast, C3a levels in AHF patients did not differ from those of the control group in the age-adjusted subgroup analysis and remained constant during hospitalisation. Concentrations of C4d, C3a and sC5b-9 were significantly higher when AHF was triggered by an infection as compared to other triggers ( p < 0.001). In addition, CAP levels significantly correlated with each other ( r = 0.64-0.76), but did not predict death within 2 years.CONCLUSIONS: Activation of complement with increased plasma levels of C4d and sC5b-9 at admission and increasing levels during AHF treatment seems to be associated with AHF, particularly when AHF was triggered by an infection. However, CAPs do not have a prognostic value in AHF.
AB - BACKGROUND: Previous studies have indicated a correlation between heart failure, inflammation and poorer outcome. However, the pathogenesis and role of inflammation in acute heart failure (AHF) is incompletely studied and understood. The aim of our study was to explore the potential role of innate immunity - quantified by complement activation products (CAPs) - in pathophysiology, responses to treatment and impacts on long-term survival in AHF.METHODS: In a prospective study enrolling 179 unselected patients with AHF, plasma concentrations of C4d, C3a and sC5b-9 were measured in a blinded fashion on the first day of hospitalisation and prior to discharge. The final diagnosis, including the AHF phenotype, was adjudicated by two independent cardiologists. Long-term follow-up was obtained. Findings in AHF were compared to that obtained in 75 healthy blood donors (control group).RESULTS: Overall, concentrations of all three CAPs were significantly higher in patients with AHF than in healthy controls (all p < 0.001). In an age-adjusted subgroup analysis, significant differences could be confirmed for concentrations of C4d and sC5b-9, and these parameters further increased after 6 days of in-hospital treatment ( p < 0.001). In contrast, C3a levels in AHF patients did not differ from those of the control group in the age-adjusted subgroup analysis and remained constant during hospitalisation. Concentrations of C4d, C3a and sC5b-9 were significantly higher when AHF was triggered by an infection as compared to other triggers ( p < 0.001). In addition, CAP levels significantly correlated with each other ( r = 0.64-0.76), but did not predict death within 2 years.CONCLUSIONS: Activation of complement with increased plasma levels of C4d and sC5b-9 at admission and increasing levels during AHF treatment seems to be associated with AHF, particularly when AHF was triggered by an infection. However, CAPs do not have a prognostic value in AHF.
KW - Acute Disease
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers/blood
KW - Cause of Death/trends
KW - Complement Activation/physiology
KW - Complement C3a/metabolism
KW - Complement C4b
KW - Complement Membrane Attack Complex/metabolism
KW - Electrocardiography
KW - Female
KW - Follow-Up Studies
KW - Heart Failure/blood
KW - Hospital Mortality/trends
KW - Hospitalization/trends
KW - Humans
KW - Male
KW - Oximetry
KW - Peptide Fragments/blood
KW - Prognosis
KW - Prospective Studies
KW - Survival Rate/trends
KW - Switzerland/epidemiology
KW - Time Factors
U2 - 10.1177/2048872617694674
DO - 10.1177/2048872617694674
M3 - SCORING: Journal article
C2 - 29064269
VL - 7
SP - 348
EP - 357
JO - EUR HEART J-ACUTE CA
JF - EUR HEART J-ACUTE CA
SN - 2048-8726
IS - 4
ER -